SCYNEXIS, Inc.
0.6870+0.00 (+0.01%)
Oct 30, 4:00:00 PM EDT · NasdaqGM · SCYX · USD
Key Stats
Market Cap
28.80MP/E (TTM)
-Basic EPS (TTM)
-0.40Dividend Yield
0%Recent Filings
8-K
GSK MOU resolves MARIO dispute
SCYNEXIS and GSK resolved their dispute over the Phase 3 MARIO study of ibrexafungerp via a binding MOU on October 14, 2025, with SCYNEXIS agreeing to wind down the trial in exchange for a $22 million payment plus $2.3 million for termination activities. GSK reaffirmed commitment to BREXAFEMME commercialization for VVC and rVVC, with NDA transfer targeted by end-2025 and FDA relaunch discussions in 2026. Milestones and royalties remain unchanged. SCYNEXIS pockets immediate cash.
10-Q
Q2 FY2025 results
Scynexis posted license revenue of $1.4 million in Q2 FY2025 ended June 30, 2025, up 85% y/y from $0.7 million, driven by a $10 million MARIO study milestone billed to GSK after resuming patient dosing in May, though YTD revenue dipped 23% y/y to $1.6 million. Operating expenses rose 10% y/y to $10.9 million, yielding an operating loss of $9.6 million, 4% wider y/y, while net loss narrowed 52% y/y to $6.9 million or $(0.14) per diluted share on 49.7 million weighted shares, thanks to a $2.2 million warrant fair-value gain offsetting higher R&D costs for SCY-247. Cash and equivalents stood at $11.0 million, with total liquidity at $46.5 million after repaying $14 million convertible debt in March; operating cash use hit $15.0 million YTD. Nasdaq flagged a bid-price deficiency below $1.00, granting until December 17, 2025, to comply. Litigation over past disclosures lingers.
8-K
Annual meeting results affirm governance
SCYNEXIS, Inc. held its 2025 Annual Meeting on June 25, where all seven board nominees secured re-election with strong majorities, averaging over 13 million for votes amid 1.2 million withheld. Shareholders ratified Deloitte & Touche LLP as auditors for the year ending December 31, 2025, with 25.5 million in favor against under 1.5 million opposed or abstaining. The advisory vote on executive pay passed handily, 12.4 million for versus 1.4 million against. Continuity intact.
8-K
Nasdaq delisting warning issued
SCYNEXIS received a Nasdaq notice on June 20, 2025, for its common stock trading below $1.00 per share over 30 consecutive business days, violating the minimum bid price rule. The company has until December 17, 2025, to achieve $1.00 for 10 straight business days and regain compliance. Failure could lead to a transfer to the Nasdaq Capital Market or delisting, with no guarantee of success. SCYNEXIS is monitoring prices and eyeing options like a reverse split.
10-Q
Q1 FY2025 results
Scynexis posted Q1 revenue of $0.3 million from its GSK license, down 81% year-over-year as MARIO study progress slowed, yet operating expenses fell 19% to $8.9 million, trimming the operating loss to $8.6 million from $9.5 million. Gross margins aren't applicable in this biotech setup, but R&D costs dropped 29% on lower manufacturing and clinical outlays for ibrexafungerp and SCY-247. Diluted EPS landed at -$0.11 on 49.4 million shares, consistent with the net loss after a $2.9 million warrant gain; no anti-dilution flagged. Cash and investments stood at $53.8 million after repaying $14 million in convertible debt, with operating cash use at $7.5 million and free cash flow negative on zero capex. The FDA lifted the MARIO hold in April 2025, but GSK's termination push risks $30 million in milestones and a $9.5 million contract asset. Cash burn quickens. Ongoing securities litigation adds uncertainty.
IPO
Website
Employees
Sector
Industry
INCY
Incyte Corporation
92.59+2.41
LXRX
Lexicon Pharmaceuticals, Inc.
1.34+0.01
NBIX
Neurocrine Biosciences, Inc.
138.04+0.02
NXEN
Nexien BioPharma, Inc.
0.01+0.00
PFE
Pfizer, Inc.
24.29+0.00
SCPH
scPharmaceuticals Inc.
5.67+0.00
SNY
Sanofi
50.94+0.26
TEVA
Teva Pharmaceutical Industries
20.03-0.20
VEXTF
Vext Science Inc.
0.20+0.00
VTRS
Viatris Inc.
10.36+0.09